Albert David
772.10
-7.50(-0.96%)
Market Cap₹- Cr
PE Ratio-
IndustryHealthcare
Company Performance:
1D-0.96%
1M-12.01%
6M-3.35%
1Y-43.82%
5Y+71.69%
View Company Insightsright
More news about Albert David
13May 25
Albert David Ltd Reports Q4 FY23 Results: EBITDA Loss Widens, Revenue Declines; Recommends Dividend
Albert David Ltd's Q4 FY23 results show a 15.94% YoY revenue decline to ₹749.00 crore. EBITDA swung to a loss of ₹48.00 crore from a profit of ₹96.00 crore in Q4 FY22. Net loss improved by 20.16% YoY to ₹103.00 crore. The company recommended a dividend of ₹5 per equity share despite financial challenges.
Albert David
772.10
-7.50
(-0.96%)
1 Year Returns:-43.82%
Industry Peers
Windlas Biotech
790.15
(+0.55%)
Jeena Sikho Lifecare
699.20
(+0.52%)
Blue Jet Healthcare
554.80
(-2.56%)
Abbott
28,850.00
(-0.14%)
Sunrest Lifescience
42.05
(-2.21%)
Zenith Drugs
54.60
(+2.25%)
Pfizer
5,001.00
(+0.57%)
FDC
414.10
(+0.24%)